Denali Therapeutics Ownership | Who Owns Denali Therapeutics?


OverviewForecastFinancialsChart

Denali Therapeutics Ownership Summary


Denali Therapeutics is owned by 19.96% institutional investors, 9.28% insiders, and 70.75% retail investors. Blackrock is the largest institutional shareholder, holding 8.82% of DNLI shares. Scottish Mortgage Ord is the top mutual fund, with 4.51% of its assets in Denali Therapeutics shares.

DNLI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDenali Therapeutics19.96%9.28%70.75%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock13.17M8.82%$305.91M
Vanguard group13.06M7.57%$215.59M
Blackrock funding, inc. /de12.72M7.37%$209.93M
Baillie gifford12.31M7.14%$203.25M
Fmr6.34M3.70%$92.06M
T. rowe price investment management5.64M3.29%$81.87M
State street5.46M3.19%$79.34M
Temasek (private)5.36M3.12%$77.77M
Norges bank5.12M2.97%$84.52M
Ubs asset management americas4.98M2.89%$82.28M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Crestline management, lp3.41M85.26%$49.52M
Foresite capital management vi1.00M5.61%$14.52M
Stempoint capital lp1.73M5.05%$25.19M
Boxer capital management250.00K1.16%$3.63M
Palo alto investors lp408.01K1.10%$5.92M
Casdin capital890.00K1.08%$12.92M
Yiheng capital management469.98K1.01%$6.82M
Monashee investment management91.62K0.85%$1.51M
Lynx1 capital management lp261.69K0.77%$3.80M
Dafna capital management168.50K0.60%$2.45M

Top Buyers

HolderShares% AssetsChange
Norges bank5.12M0.01%5.12M
Holocene advisors, lp3.14M0.10%2.73M
T. rowe price investment management5.64M0.05%2.39M
Goldman sachs group3.84M0.01%1.67M
Vanguard group13.06M0.00%1.06M

Top Sellers

HolderShares% AssetsChange
Wellington management group llp59.23K0.00%-5.61M
Price t rowe associates inc /md/4.57M0.01%-2.01M
Flagship pioneering---1.36M
Fmr6.34M0.00%-1.20M
Gilder gagnon howe---1.17M

New Positions

HolderShares% AssetsChangeValue
Norges bank5.12M0.01%5.12M$84.52M
Foresite capital management vi1.00M5.61%1.00M$14.52M
Axa investment managers294.73K0.01%294.73K$4.28M
Lynx1 capital management lp261.69K0.77%261.69K$3.80M
Schonfeld strategic advisors226.20K0.02%226.20K$3.28M

Sold Out

HolderChange
Truvestments capital-1.00
Toronto dominion bank-2.00
Dinuzzo private wealth-2.00
Global financial private client-5.00
Wealthtrak capital management-10.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202569-71.60%34,419,053-74.60%190.32%37-70.63%15-76.92%
Sep 30, 202584-62.83%32,008,693-75.36%180.33%39-67.77%28-56.25%
Jun 30, 20252304.07%137,233,4273.48%801.33%12214.02%66-17.50%
Mar 31, 2025220-3.51%132,840,2763.83%771.36%108-14.96%8035.59%
Dec 31, 20242272.71%127,936,9431.24%751.36%1258.70%603.45%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Scottish Mortgage Ord7.04M4.51%515.41K
Vanguard Health Care Inv4.40M3.03%-5.17M
Vanguard Total Stock Mkt Idx Inv4.20M2.69%15.98K
Vanguard US Total Market Shares ETF3.33M2.29%-161.11K
State Street® SPDR® S&P® Biotech ETF3.30M2.12%-17.68K
iShares Russell 2000 ETF3.19M2.04%1.06M
Vanguard US Growth Investor3.04M1.95%219.47K
Baillie Gifford US Equity Growth3.04M1.95%219.47K
Vanguard Small Cap Index3.00M1.92%-1.42K
T. Rowe Price Health Sciences2.22M1.52%-278.46K

Recent Insider Transactions


DateNameRoleActivityValue
Jan 06, 2026Watts Ryan J. President and CEOSell$580.77K
Jan 06, 2026Schuth Alexander O. COFO and SecretarySell$284.10K
Dec 11, 2025BAKER BROS. ADVISORS LP-Buy$1.91K
Dec 11, 2025BAKER BROS. ADVISORS LP-Buy$20.95K
Aug 12, 2025Schuth Alexander O. COFO and SecretarySell$39.88K

Insider Transactions Trends


DateBuySell
2026 Q1-2
2025 Q42-
2025 Q3-4
2025 Q2--
2025 Q1-8

DNLI Ownership FAQ


Who Owns Denali Therapeutics?

Denali Therapeutics shareholders are primarily institutional investors at 19.96%, followed by 9.28% insiders and 70.76% retail investors. The average institutional ownership in Denali Therapeutics's industry, Biotech Stocks , is 381.47%, which Denali Therapeutics falls below.

Who owns the most shares of Denali Therapeutics?

Denali Therapeutics’s largest shareholders are Blackrock (13.17M shares, 8.82%), Vanguard group (13.06M shares, 7.57%), and Blackrock funding, inc. /de (12.72M shares, 7.37%). Together, they hold 23.77% of Denali Therapeutics’s total shares outstanding.

Does Blackrock own Denali Therapeutics?

Yes, BlackRock owns 8.82% of Denali Therapeutics, totaling 13.17M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 305.91M$. In the last quarter, BlackRock increased its holdings by 974.71K shares, a 7.99% change.

Who is Denali Therapeutics’s biggest shareholder by percentage of total assets invested?

Crestline management, lp is Denali Therapeutics’s biggest shareholder by percentage of total assets invested, with 85.26% of its assets in 3.41M Denali Therapeutics shares, valued at 49.52M$.

Who is the top mutual fund holder of Denali Therapeutics shares?

Scottish Mortgage Ord is the top mutual fund holder of Denali Therapeutics shares, with 4.51% of its total shares outstanding invested in 7.04M Denali Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools